Offering genetic testing at the provider’s office at the time of diagnosis effectively increased the number of people with gynecological cancers who underwent testing. That’s…
Corcept Therapeutics is launching a Phase 2 clinical trial to evaluate the safety and efficacy of relacorilant as a triple combination treatment — with…
A Phase 1 clinical trial testing Nikang Therapeutics’ oral therapy NKT3964 in people with certain advanced or metastatic solid tumors, including gynecological cancers,…
Calidi Biotherapeutics has begun recruiting adults with high-grade glioma for a Phase 1b/2 clinical trial to study the effects of multiple doses of…
Allarity Therapeutics will soon start recruiting patients at several U.S. sites for a new dosing protocol in its Phase 2 trial testing stenoparib…
The U.S. Food and Drug Administration (FDA) has granted fast-track status to CUSP06, Oncusp Therapeutics’ treatment candidate for platinum-resistant ovarian cancer. This designation…
A first patient with relapsed/refractory multiple myeloma (RRMM) treated with CT0590, Carsgen Therapeutics’ CAR T-cell therapy, showed a complete response to the…
The Lundin Cancer Fund has donated $4 million to the Canadian Cancer Society to create the Glioblastoma Research Program, a five-year initiative to…
About a third of women with cyclin E1+ platinum-resistant ovarian cancer (PROC) responded to treatment with azenosertib, an experimental therapy by Zentalis. That’s according…
In people with acute myeloid leukemia (AML), changes in the gene profile of blood-forming stem cells, leading to a more youthful blood cell profile, could…
